90%

The 5-year survival rate among female patients diagnosed in the United States.This rate drops to
82% after 10 years.

12%

1 out of 8 women, will develop an invasive form of cancer in their lifetime.

2 million  

New cases were diagnosed worldwide in 2018. 

 No. 1

Breast cancer is the No. 1 cancer among women, and the second most deadly, after lung cancer.

21%

Of patients are under the age of 49 and 43% over the age of 65. *Source - World Cancer Research Fund International

*Source - World Cancer Research Fund International
Private-sector investors also have a role to play in this system,
By funding the most promising projects.
Are they still showing interest?
If we look to the past, in venture capital, there were certain voids not being filled, and companies had to engage in fierce competition to attract investors, especially in Europe. When coronavirus came along, it seemed like venture capital might get “crowded-out” towards other treatment areas. That wasn’t the case, however, which just goes to show how expansive research is today and how promising are innovations for the future.

Lastly, I would say that venture capital in the healthcare industry is not only gaining ground in most European countries, but also improving. As a general rule, companies have the necessary funds to do their work.

Those with the right innovation have no trouble in that department. I would almost venture to say that, in some countries, there is more capital than big ideas. Which is why is it also important for investors to conduct an in-depth analysis of the projects they plan to invest in, no matter what the type of company (publicly traded or private), by relying on renowned experts.

That’s what we at Candriam offer, with our team of investment-savvy scientists and our exclusive valuation models, which have proved their worth for nearly 20 years now, even in an environment as complex as that created by the coronavirus.
Funds

Candriam Equities L Oncology Impact

Latest analyses

  • Oncology

    World Cancer Day: How PRISM is helping to Close the Gap

    The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer.
  • Oncology, ISR, ESG

    Octobre rose

    À l’occasion d’Octobre Rose, mois de sensibilisation aux cancers du sein, Rudi Van Den Eynde, Head of Thematic Global Equity, fait le point sur la maladie et les défis posés par l'épidémie.

Find out more

  • All our publications
  • Meet our experts
  • Candriam in the press

Recherche rapide

Obtenez des informations plus rapidement en un seul click

Recevez des informations directement dans votre boîte e-mail